Background: Lung cancer (LC) is causing more than 1.3 million deaths worldwide annually. Early detection of LC is critical for survival but despite recent advancements in LC diagnostics most patients are still diagnosed at advanced stages of the disease. The situation is further complicated by high intratumor heterogeneity and general diversity of lung malignancies. Insights into cancer genetics have kindled interest in molecular cancer diagnostics. One of the lucrative sources of prospective LC biomarkers is cellfree circulating miRNAs. These small non-coding RNAs are frequently deregulated in LC. It is also known that miRNAs can travel in bodily fluids for extended periods of time, shielded from degradation by membrane vesicles or other biopolymers. Recently, specific subsets of miRNAs associated with tumor phenotypes and disease progression have been found circulating in blood of cancer patients and suggested as potential biomarkers for LC. Methods: In the present study, we have investigated the profiles of circulating miRNAs in blood plasma of LC patients and healthy individuals (HD) in order to identify potential markers for lung cancer diagnostics. Small RNAs were isolated from blood plasma of 20 LC patients and 10 healthy individuals (HD) using protocol reported earlier (Zaporozhchenko et al, Anal Biochem, 2015) . Profiles of miRNA expression were obtained using miRCURY LNA miRNA qPCR Panels Plasma/Serum (Exiqon). Ratio based normalization was applied to all miRNA's with call rate higher than 80%.
Results: Statistical comparison using two-way ANOVA identified 241 ratios (98 individual miRNAs) with significantly different expression between LC patients and HD (p < 0.05 after Benjamini-Hochberg correction). Using LASSO penalization models and manual filtering of miRNAs associated with haemolysis, 7 miRNA ratios were identified as best predictors of cancer. Extended set of miRNAs (n ¼ 19) was selected for further verification in an independent sample of 30 LC patients, 20 HD and 10 patients with hyper-and metaplastic endobronchitis using custom miRCURY LNA miRNA qPCR Pick & Mix Panel. Conclusions: Based on expression in both data sets 5 ratios containing 7 miRNAs were selected for further validation in an extended cohort of LC and cancer-free individuals. Background: DNA methylation is an epigenetic determinant of gene expression. Cytochrome P450 (CYP1A1) is a phase 1 xenobiotic metabolizing enzyme. Glutathione S-transferase P1 (GSTP1) detoxifies metabolites and regulates cellular chemical stress and death. Methylation changes in these genes could play a role in the incidence of cancer. Our aims were to analyze DNA-methylation of selected CpG islands in the CYP1A1 and GSTP1 genes at baseline in subjects who had incident cancer and paired controls, and to determine if DNA methylation in cancer patients changed from baseline to the time close to cancer diagnosis. Methods: We followed-up 1094 subjects (aged: 6766years) of the PREDIMEDValencia study prospectively from 2003 to 2014. Cancer incidence was a secondary outcome in our trial. We analyzed 69 cases of incident cancer (lung, breast and colon) during this follow-up period, and 69 paired controls free of cancer. We analyzed DNAmethylation levels of the CYP1A1 and GSTP1 genes at baseline in both groups. Quantitative DNA methylation analysis was undertaken by MALDI-TOF mass spectrometry. We evaluated methylation levels on chromosome 15 (region: 74726090 -74726460 base pairs from promoter) and chromosome 11 (region: 67583556-67583896 base pairs from promoter). Results: We detected statistically significant differences in DNA methylation levels at baseline in the CYP1A1 and GSTP1 genes between cancer cases and controls (P=0.008 for the CpG site 26-27 of the CYP1A1 gene and P=0.049 for the CpG 10-11 island at the GSTP1 gene). We detected statistically significant changes in DNA methylation prospectively in cancer patients. DNA methylation at the CpG 4 (CYP1A1 gene) was 0.02060.034 at baseline vs 0.00660.013 close to cancer diagnosis (P=0.044). For the GSTP1 gene, methylation of the CpG 34-39 prospectively increased from 0.32760.046 at baseline to 0.34560.053 (P=0.014) close to cancer diagnosis. Conclusions: We have detected differences in DNA-methylation of selected CpG Islands of the CYP1A1 and GSTP1 genes at baseline, between future diagnosed cancer subjects and cancer-free controls. Moreover, in patients subsequently diagnosed with cancer, a change in DNA methylation was observed between baseline and close to the time of cancer diagnosis. This suggests a dynamic influence of DNA methylation that could be modulated for prevention. Clinical trial identification: Controlled-trials.com number ISRCTN35739639 Legal entity responsible for the study: Spanish Government's Instituto de Salud Carlos III and University of Valencia Funding: Instituto de Salud Carlos III Disclosure: All authors have declared no conflicts of interest.
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A.A. Henriques, P. Matos, P. Jordan Human Genetics Department, Instituto Nacional de Sa ude Doutor Ricardo Jorge, Lisbon, Portugal
Background: Cancer cells require increased glucose supply to sustain proliferation. One mechanism involves increased expression of glucose transporter (GLUT) genes. But insulin has revealed that protein phosphorylation is another key mechanism in glucose uptake regulation: insulin binding to responsive cells triggers a signalling cascade with phosphorylation of TBC1D4, a negative regulator of endosomal GLUT trafficking, abstracts Annals of Oncology so that more transporters are inserted into the plasma membrane. Previous work from the host lab has identified the family of WNK protein kinases and shown that WNK1 can also phosphorylate TBC1D4 and promote GLUT translocation to the cell surface. Our objective is to understand the contribution of WNK1 to glucose uptake in colorectal cancer cells. Our objective is to understand the contribution of WNK1 to glucose uptake in colorectal cancer cells. Methods: To characterize the role of WNK1, various colorectal cell lines were first cultivated with different glucose concentrations. Levels of GLUT1 at the cell surface were compared under these conditions and the effect of depleting WNK1 expression by siRNA determined. Results: For selected conditions, key cell cycle or apoptotic marker proteins were analysed by Western blot and revealed higher apoptotic and cell-cycle arrest phenotypes in WNK1-depleted cells cultured in low glucose medium. In order to dissect key phosphorylation events involved in GLUT1 regulation, mass spectrometry analysis revealed that WNK1 phosphorylates TBC1D4 and the functionally related TBC1D1 at unique Serine residues. The corresponding phospho-mimetic mutants are currently being tested for their ability to increase GLUT1 translocation. Conclusions: Together, these studies will elucidate the molecular details regulating the translocation of glucose transporters in cancer cells and have the potential to identify novel therapeutic targets. Legal entity responsible for the study: Peter Jordan Funding: Fundac¸ão para a Ciência e Tecnologia BioISI -Biosystems and Integrative Sciences Institute Disclosure: All authors have declared no conflicts of interest.
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Background: In colon cancer distinct genetic subtypes have been described, one of which involves overexpression of RAC1b, a variant generated by alternative splicing. Aberrant splicing is known to occur in cancer and can be caused by mutation in a gene or splicing factor but also represents a dynamic response to oncogene-induced cellular signaling and in this case it may be pharmacologically targeted. Here we explore how signaling pathways are involved in the deregulation of alternative RAC1b splicing in colorectal tumor cells. Methods: HT29 colorectal cells represent serrated colorectal tumors with BRAF gene mutation V600E in one allele and RAC1b overexpression. Cells were transfected with shRNA vectors directed against target candidate protein kinase transcripts and their effects on RAC1b levels analyzed 24h later by Western Blot and qRT-PCR. Treatment with kinase inhibitors or anti-inflammatory drugs was performed 24h prior to cell lysis. Results: Two kinases, SRPK1 and GSK3b, were found required to sustain RAC1b levels and both were shown to act upon the phosphorylation of splicing factor SRSF1, which binds to and promotes the inclusion of the alternative exon in RAC1b. SRPK1 knockdown or pharmacological inhibition reduced SRSF1 phosphorylation decreasing its nuclear translocation and concomitantly RAC1b splicing. The same regulatory pathway was also found to be controlled by GSK3b. Interestingly, GSK3b phosphorylation was identified to serve as target for the anti-inflammatory drug ibuprofen, which inhibits RAC1b overexpression.
Conclusions:
Together, our results demonstrate that oncogenic signal transduction pathways deregulate alternative splicing and this may be drug revertable. Legal entity responsible for the study: Peter Jordan Funding: Fundac¸ão para a Ciência e Tecnologia Disclosure: All authors have declared no conflicts of interest. Background: Foreseeing treatment outcome in cancer patients is still a challenge that needs to be addressed. Tumors are complex structures, where the interaction between the tumor cells and the surrounding microenvironment regulates key processes in cancer progression, such as angiogenesis, evasion and modulation of the immune system response, and invasiveness. These interactions confer tumors a high heterogeneity not only inter-patient but also intra-patient. In vitro experimental models have been developed to preserve this heterogeneity present on tumor biopsies by the use of rotary wall and perfused bioreactors. However, the complexity and size of the bioreactors prevent from visual inspection of the sample and the realization of a high-throughput screening. The present work focuses on the combination of microfabrication techniques and microfluidics to downsize classic experimental models. The developed methodology requires only microliter size sample, and allows real time optical inspection. Methods: A microscopy slide size optically transparent microfluidic bioreactor (mbioreactor) was designed and developed to preserve high cellularity on complex samples through constant perfusion. Colorectal carcinoma (CRC) biopsies were taken after previous patient consent was obtained. CRC biopsies were perfused by cell culture media in the mbioreactor during one week. After perfusion, CRC biopsies were histologically processed, stained and characterized by immunofluorescence. Results: High cellularity was observed in CRC biopsies after one week of perfusion. Stromal and parenchymal preservation was confirmed by both, histological staining and immunofluorescence. Conclusions: The use of microfluidic bioreactors can be successfully used to preserve CRC biopsies, maintaining cell heterogeneity while allowing optical inspection. The use of small sample volumes (microliters) allows high throughput screening using regular biopsy samples, a key feature to achieve personalized treatments in cancer. Legal entity responsible for the study: University of Zaragoza Funding: None Disclosure: All authors have declared no conflicts of interest. Background: The colorectal cancer is one of the most common cancers in the world being the main cause of death the metastatic spread to the liver. During metastatic progression, a stromal and tumor cell crosstalk mediated by hepatic ICAM-1 and tumor LFA-1 interaction modulate the tumor microenvironment through an inflammatory and immune response. Additionally, a matrix remodeling and angiogenic response is also associated with tumor progression. The main cell type associated to these processes is the fibroblast associated to the tumor. Thus, the aim of this work is to elucidate the effect of ICAM-1/LFA-1 interaction during the angiogenic and desmoplasic response during liver metastatic progression. Methods: To do so, the effect of ICAM-1/LFA-1 interaction on the tumor progression and recruitment of cancer associated fibroblasts was analyzed by an experimental metastasis assay in vivo and a modified Boyden chamber migration assays in vitro, after either activation of tumor cells with sICAM-1 or blocking of ICAM-1/FA-1 interaction. In addition, the effects of LFA-1 tumor depletion on tumor migratory potential induced by tumor-activated fibroblasts derived factors were analyzed. Also, the effect of the modulation of this pathway on MMPs protein and angiogenic gene expression levels was measured by zymography and qPCR, respectively. Results: In vivo and in vitro assays showed an increase on fibroblast and tumor cells recruitment after activation of tumor LFA-1 activation by binding with sICAM-1 which was abrogated after blocking of LFA-1. Moreover, the expression levels of MMPS and other proangiogenic factors were decrease after the blockage of ICAM-1/LFA-1 interaction. Also, the collagen deposition was increased after LFA-1 activation and diminished by LFA-1 blocking.
The interaction of ICAM-1 with tumor LFA-1 favors the recruitment of fibroblast within the tumor mediated by a modulation of pro-desmoplasic factors. This favors the remodeling of the tumor stroma and the angiogenic response and promotes tumor metastatic progression. Thus, LFA-1ICAM-1 interaction might be pointed out as a potential target for therapy of the metastatic disease. Legal entity responsible for the study: Department of Cellular Biology and Histology, University of the Basque Country, School of Medicine and Nursery Funding: Basque Government Disclosure: All authors have declared no conflicts of interest.
